Latest News

Inpex (TSE:1605) has just wrapped up FY 2025 with fourth quarter revenue of ¥490,704 million and basic EPS of ¥86.17, while trailing twelve month figures sit at ¥2.0 trillion in revenue and EPS of ¥337.94, giving investors a clear view of both the latest quarter and the full year run rate. Over recent periods, revenue has moved from ¥518,280 million and EPS of ¥115.17 in Q4 2024 to ¥490,704 million and EPS of ¥86.17 in Q4 2025, with trailing net profit margin at 19.6% compared with 18.9% a...

Iveco Group (BIT:IVG) closed out FY 2025 with fourth quarter revenue of €4.0b and basic EPS of €0.46, setting the tone for how the full year’s performance will be read against earlier quarters. The company has seen revenue move from €4.6b and EPS of €0.91 in Q4 2024 to €4.0b and €0.46 in Q4 2025, while trailing twelve month EPS stood at €0.87, so investors are likely to focus on how these earnings and margin trends fit with expectations for future growth. With trailing net profit margin at...

Cochlear (ASX:COH) has reported its H1 2026 results with trailing twelve month revenue of A$2.3b and basic EPS of A$5.28, giving investors a clear read on both top line scale and earnings power. The company has seen half year revenue move from A$1,137.1 million in H2 2024 to A$1,171.8 million in H1 2025 and A$1,171.3 million in H2 2025, while basic EPS shifted from A$2.53 to A$3.13 and then A$2.81 over the same periods. This sets the backdrop for a margin story that investors will parse...

What is moving Amphastar Pharmaceuticals now? Amphastar Pharmaceuticals (AMPH) has drawn investor attention after its recent share performance, with the stock around $27.55 and short term returns mixed between the past week, month and past 3 months. See our latest analysis for Amphastar Pharmaceuticals. At around $27.55, Amphastar Pharmaceuticals has given investors a mixed ride, with recent share price returns over the past week and month soft, while the 90 day share price return of 5.72%...

Organigram Global (TSX:OGI) is back in focus after reporting first quarter 2026 results that shifted from a net loss to net income, with higher sales and revenue, as well as positive earnings per share. See our latest analysis for Organigram Global. Despite the swing back to net income, Organigram Global’s share price has had a tough run, with a 30 day share price return of a 26.6% decline and a 1 year total shareholder return of a 9.4% decline. This may suggest that recent enthusiasm around...

In early February 2026, PotlatchDeltic Corporation was removed from the NASDAQ Composite Index, while multiple long-running ESOP-related shelf registrations for common stock were formally closed. This combination highlights how a technical index change, rather than routine employee stock plan administration, can have an outsized influence on trading flows and investor attention. Next, we’ll examine how PotlatchDeltic’s removal from the NASDAQ Composite Index could affect its existing...

Nick Scali (ASX:NCK) has released its H1 2026 scorecard, with investors already eyeing how the latest numbers fit into the broader trend in revenue and EPS. The company has seen half year revenue move from A$241.6 million in H2 2024 to A$251.1 million in H1 2025 and then A$244.2 million in H2 2025, while basic EPS shifted from A$0.457 to A$0.351 and then A$0.324 over the same periods. This gives investors a clear view of how recent trading has flowed through to the bottom line. With net...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Travel + Leisure fair value estimate is US$100 Current share...

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Some Ameriprise Financial, Inc. ( NYSE:AMP ) shareholders may be a little concerned to see that the Chairman & CEO...

As the Canadian market navigates a landscape where technology stocks are experiencing valuation adjustments due to AI-driven disruptions and increased capital spending, investors are re-evaluating their strategies. Amidst this backdrop, penny stocks—often associated with smaller or newer companies—offer intriguing opportunities for those looking beyond the established giants. While the term might seem outdated, these stocks continue to provide potential growth at lower price points when...

To the annoyance of some shareholders, EROAD Limited ( NZSE:ERD ) shares are down a considerable 28% in the last month...

Sylvamo (SLVM) just posted its FY 2025 third quarter numbers, reporting revenue of US$846 million and basic EPS of US$1.43 alongside net income of US$57 million. The company’s quarterly revenue moved from US$970 million in Q4 2024 to US$821 million in Q1 2025, US$794 million in Q2, and then US$846 million in Q3. Over the same period, basic EPS went from US$1.98 to US$0.67, US$0.37, and then US$1.43. These shifts give investors more detail for evaluating how recent performance trends relate to...

As February begins, the United States stock markets have shown strong performance, with major indices like the Dow Jones Industrial Average and S&P 500 experiencing significant gains. This positive momentum in the market presents an opportunity to explore stocks that may be undervalued, potentially trading below their estimated intrinsic value. Identifying such stocks requires a keen understanding of current market conditions and economic indicators to evaluate their true potential amidst...

As February begins, U.S. stock markets have shown a strong start with major indexes like the Dow Jones Industrial Average and S&P 500 posting significant gains, reflecting positive investor sentiment amid economic developments such as a new trade deal with India. In this thriving market environment, companies that exhibit high insider ownership often signal confidence from those who know the business best, making them potentially attractive options for growth-focused investors seeking...

As February 2026 begins, major U.S. stock indexes have shown robust performance, with the Dow Jones Industrial Average gaining 515 points and the S&P 500 nearing record highs. This market momentum sets a promising backdrop for exploring investment opportunities in various sectors. Despite its somewhat outdated terminology, the concept of penny stocks remains significant as these smaller or newer companies can offer a blend of affordability and growth potential when backed by strong financials...

As February 2026 begins, the U.S. stock market is experiencing a surge, with major indices like the Dow Jones and S&P 500 showing strong performances despite recent economic uncertainties such as delayed jobs data due to a government shutdown and shifting trade dynamics. In this vibrant yet complex environment, discovering lesser-known stocks that have potential for growth can be an intriguing prospect for investors looking to diversify their portfolios amidst evolving market conditions.

Cohu (NasdaqGS:COHU) reported strong Q4 revenue growth alongside a larger than expected quarterly loss. Management pointed to increasing demand tied to high-bandwidth memory and AI related markets. The company highlighted design wins and solid order activity in automotive, computing, and advanced packaging. Cohu, which supplies test and handling equipment for semiconductor manufacturing, is focusing on areas where chip complexity and performance requirements are rising. High-bandwidth...

Primerica (PRI) has capped FY 2025 with fourth quarter revenue of US$853.7 million, basic EPS of US$6.16 and net income of US$197.0 million, alongside a combined ratio of 66.3% that gives an immediate read on underwriting profitability. The company has seen quarterly revenue move from US$803.4 million and basic EPS of US$4.99 in Q4 2024 to US$853.7 million and US$6.16 in Q4 2025. Trailing 12 month revenue sits at about US$3.3 billion and EPS at US$23.02, setting the stage for investors to...

Similarweb (SMWB) has drawn fresh attention after launching AI Studio, an enterprise AI intelligence platform that lets clients query its extensive digital data through conversational research, deep reports, and auto generated dashboards for business decision support. See our latest analysis for Similarweb. The AI Studio launch and Bloomberg Terminal integration arrive during a weak patch for the stock, with Similarweb’s 30 day share price return of 39.16% and year to date share price return...

Bitdeer Technologies Group (NasdaqCM:BTDR) just posted its FY 2025 third quarter numbers with revenue of US$169.7 million, a basic EPS loss of US$1.28 per share and net income loss of US$266.7 million, putting profitability firmly in focus for investors. The company has seen quarterly revenue move from US$70.1 million in Q1 2025 and US$155.6 million in Q2 2025 to US$169.7 million in Q3. Over the same period, EPS moved from a profit of US$2.15 in Q1 to losses of US$0.76 and US$1.28 in Q2 and...

Vobile Group (SEHK:3738) has drawn fresh attention after announcing a collaboration with Finloop Finance Technology to tokenize offshore real world assets tied to cultural and creative intellectual property, with the aim of building a compliant IP backed digital asset ecosystem. See our latest analysis for Vobile Group. The Finloop agreement lands at a time when momentum in Vobile Group’s shares has been picking up, with a 7 day share price return of 37.09% and a year to date share price...

Safehold (NYSE:SAFE) received an S&P credit rating upgrade to A- with a stable outlook. The company announced a share buyback program alongside plans to monetize more of its unrealized capital appreciation, known as "Carats." Management outlined an expansion of ground lease originations, including a focus on affordable housing and broader geographic reach. Safehold, trading at $14.84, is working to reposition itself in the eyes of both credit markets and equity investors. The stock is up...

Camurus AB reported its fourth-quarter and full-year 2025 results, with full-year sales rising to SEK 2,265.38 million and net income to SEK 735.57 million, while issuing 2026 guidance for revenues of SEK 2.60–2.90 billion and operating result of SEK 0.90–1.20 billion. Alongside these results, Camurus highlighted 2025 milestones including EU and UK approvals for Oxyesa in acromegaly and progress in long-acting metabolic therapies, underlining how its product pipeline and regulatory traction...